Table 2.
Case-control, cross-sectional studies addressing the potential of proton-pump inhibitors to modulate the metabolism of magnesium. Reports disclosing a significant relationship between use of these drugs and metabolism of magnesium are bold.
Reference | Country | Patients | Results |
---|---|---|---|
Alhosaini et al. [5] | USA | 62 hemodialysis patients | Use of proton-pump inhibitors was associated (P < 0.05) with hypomagnesemia |
| |||
Biyik et al. [6] | Turkey | 238 outpatients | Magnesemia was similar in users of proton-pump inhibitors (N = 154) and nonusers (N = 84) |
| |||
Danziger et al. [7] | USA | 11,490 patients admitted to an intensive care unit | Hypomagnesemia was disclosed exclusively (P < 0.01) in patients concurrently treated with both proton-pump inhibitors and diuretics. Use of histamine type-2 receptor antagonists (with or without diuretics) was not associated with hypomagnesemia |
| |||
El-Charabaty et al. [8] | USA | 262 intensive care patients with cardiac arrhythmias | Use of proton-pump inhibitors prior to admission was associated with tendency to hypomagnesemia (r = 0.82) |
| |||
Faulhaber et al. [9] | Brazil | 151 internal medicine patients | No cases of hypomagnesemia were detected on treatment with proton-pump inhibitors |
| |||
Gau et al. [10] | USA | 487 inpatients | Use of proton-pump inhibitors was associated with lower magnesemia (P < 0.005) and with a 2.5-fold increased risk of hypomagnesemia |
| |||
Kim et al. [11] | Korea | 1356 patients | Magnesemia was lower (P < 0.0001) in users of proton-pump inhibitors (N = 112) than in nonusers (N = 1,244). Concurrent treatment with cisplatin (P < 0.05) or carboplatin (P < 0.01) further exacerbated hypomagnesemia |
| |||
Koulouridis et al. [12] | USA | 804 well-matched inpatients | Use of proton-pump inhibitors prior to admission was not associated with hypomagnesemia |
| |||
Lindner et al. [13] | Switzerland | 5,118 emergency department patients | Hypomagnesemia was significantly (P < 0.0001) associated with the use of proton-pump inhibitor or both proton-pump inhibitors and diuretics |
| |||
Markovits et al. [14] | Israel | 95,205 outpatients | Users of proton-pump inhibitors (N = 22,458) presented frequently with hypomagnesemia (P < 0.005). Use of histamine type-2 receptor antagonists was not associated with hypomagnesemia |
| |||
Sumukadas et al. [15] | United Kingdom | 196 elderly unit patients | Magnesemia was lower (P < 0.05) in users of proton-pump inhibitors with poor renal function |
| |||
Van Ende et al. [16] | Belgium | 512 renal transplant recipients | Use of proton-pump inhibitors was not a predictor of hypomagnesemia |
| |||
William et al. [17] | USA | 278 outpatients | Magnesiuria was reduced (P < 0.02) in users of proton-pump inhibitors. Diuretics did not modulate the effect of proton-pump inhibitors on magnesiuria |
| |||
Zipursky et al. [18] | Canada | 1,830 inpatients | Patients admitted with hypomagnesemia were frequently (odds ratio = 1.43) on proton-pump inhibitors. Diuretics further exacerbated the tendency to hypomagnesemia (odds ratio = 1.73). Use of histamine type-2 receptor antagonists was not associated with hypomagnesemia |